Evolent Health, Inc. - Class A Shares (EVH) Stock
Key stats
- Market cap
- $516.68M
- Price / Earnings ratio
- -1.1x
- EPS (TTM)
- -$0.68
- Volume
- Loading
- 52-week high
- $8.30
- 52-week low
- $2.10
Source: third-party data provider, as of October 18, 2026
Compare with EVH
Recent news

Evolent Health Q2 Earnings Call Highlights
Evolent Health Q2 Earnings Call Highlights
EVH

Compared to Estimates, Evolent Health (EVH) Q2 Earnings: A Look at Key Metrics
Compared to Estimates, Evolent Health (EVH) Q2 Earnings: A Look at Key Metrics
EVH

Evolent Health (EVH) Tops Q2 Earnings and Revenue Estimates
Evolent Health (EVH) Tops Q2 Earnings and Revenue Estimates
EVH

Healthcare IT is the Next AI Growth Story: 3 Stocks to Buy Now
Healthcare IT is the Next AI Growth Story: 3 Stocks to Buy Now
EVH
Technical indicators
- RSI 14
- 61.41
- MACD 12/26/9
- 0.16
- EMA 9 of MACD
- 0.02
- MACD histogram
- 0.14
- SMA 50
- $4.16
- Price above SMA 50
- EMA 50
- $4.14
- Price above EMA 50
- SMA 200
- $3.84
- Price above SMA 200
- EMA 200
- $4.09
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of October 16, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 5 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
The market is expecting earnings per share of -$0.01 for this quarter. The company has not yet shared when it is announcing earnings.
Source: third-party data provider
Latest news

Evolent Health Q2 Earnings Call Highlights
Evolent Health Q2 Earnings Call Highlights
EVH

Compared to Estimates, Evolent Health (EVH) Q2 Earnings: A Look at Key Metrics
Compared to Estimates, Evolent Health (EVH) Q2 Earnings: A Look at Key Metrics
EVH

Evolent Health (EVH) Tops Q2 Earnings and Revenue Estimates
Evolent Health (EVH) Tops Q2 Earnings and Revenue Estimates
EVH

Healthcare IT is the Next AI Growth Story: 3 Stocks to Buy Now
Healthcare IT is the Next AI Growth Story: 3 Stocks to Buy Now
EVH

Should You Buy Evolent Health (EVH) After Golden Cross?
Should You Buy Evolent Health (EVH) After Golden Cross?
EVH

Strength Seen in Evolent Health (EVH): Can Its 9.5% Jump Turn into More Strength?
Strength Seen in Evolent Health (EVH): Can Its 9.5% Jump Turn into More Strength?
EVH

Agentic AI Powers U.S. Healthcare Stocks
Agentic AI Powers U.S. Healthcare Stocks
EVH

Evolent Health Q1 Earnings Call Highlights
Evolent Health Q1 Earnings Call Highlights
EVH

Compared to Estimates, Evolent Health (EVH) Q1 Earnings: A Look at Key Metrics
Compared to Estimates, Evolent Health (EVH) Q1 Earnings: A Look at Key Metrics
EVH

Evolent Health (EVH) Reports Q1 Loss, Misses Revenue Estimates
Evolent Health (EVH) Reports Q1 Loss, Misses Revenue Estimates
EVH
About Evolent Health, Inc. - Class A Shares
Evolent Health Inc is engaged in healthcare delivery and payment. The company supports health systems and physician organizations in their migration toward value-based care and population health management. It provides specialty care management services in oncology, cardiology, musculoskeletal markets and holistic total cost of care management along with an integrated platform for health plan administration and value-based business infrastructure under one go to market package. The primary solutions provided by the company include specialty care management services, total cost of care management, and administrative services.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Seth Barrie Blackley | Co-Founder, CEO & Director | 1979 |
| Mr. Mario Marques Ramos | Chief Financial Officer | 1972 |
| Ms. Katie DiPerna Cook | Chief Operating Officer | — |
| Mr. Dan McCarthy | President | 1985 |
| Mr. Jonathan David Weinberg J.D. | Chief Legal Officer, General Counsel & Secretary | 1968 |
| Mr. John Paul Johnson | Chief Strategy Officer | 1984 |
| Mr. Aammaad Shams | Chief Accounting Officer | 1984 |
| Mr. Robert Cruz | Chief Technology Officer | — |
| Ms. Jessica White | Chief Information Officer | — |
| Dr. John Tam M.D. | Chief Growth Officer | — |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of October 18, 2026
Technical indicators
- RSI 14
- 61.41
- MACD 12/26/9
- 0.16
- EMA 9 of MACD
- 0.02
- MACD histogram
- 0.14
- SMA 50
- $4.16
- Price above SMA 50
- EMA 50
- $4.14
- Price above EMA 50
- SMA 200
- $3.84
- Price above SMA 200
- EMA 200
- $4.09
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of October 16, 2026. Technical data, not a recommendation.
Analyst views
5 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $6.00
- Average
- $6.00
- High
- $6.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -3.8 | -11.5 | +9.1 | |||||||||
| 2022 | -15.2 | +10.4 | +17.9 | -14.7 | -1.8 | +7.5 | +9.2 | +5.6 | -2.8 | -14.1 | -0.5 | -0.6 |
| 2023 | +19.4 | +7.9 | -8.0 | +13.3 | -20.0 | +1.6 | +1.0 | -16.1 | +4.4 | -9.2 | +15.7 | +14.2 |
| 2024 | -11.6 | +14.1 | -4.7 | -13.1 | -22.3 | -9.1 | +26.7 | +42.5 | -8.8 | -13.7 | -44.9 | -11.5 |
| 2025 | -9.1 | -11.9 | +8.0 | +1.9 | -25.1 | +48.7 | -13.6 | -3.3 | -12.0 | -16.9 | -37.5 | +0.0 |
| 2026 | -17.5 | -0.3 | -36.3 | +68.9 | +5.3 | +30.0 | -46.2 | +43.3 | -18.5 | +43.7 |



